Jupiter Endovascular
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
155 Jefferson Dr # 100, Menlo Park, Cali...Phone Number
(888) 271-9499Website
www.jupiterendo.comRevenue
$22.8 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Jupiter Endovascular
Jupiter Endovascular is a U.S.-based medical technology startup focused on advancing minimally invasive cardiovascular treatments through innovative catheter-based systems. Headquartered in Menlo Park, California, the company develops next-generation endovascular devices designed to improve the precision, stability, and effectiveness of interventional procedures. At the core of its innovation is a proprietary platform known as Transforming Fixation (TFX) technology. This technology enables catheters to transition from flexible to rigid once inside the body, allowing physicians to navigate complex vascular pathways easily and then stabilize the device during treatment. This approach helps overcome limitations of traditional catheters, which are often too rigid or lack control in delicate anatomical structures.Explore more
Popular SearchesJupiter Endovascular IncSIC Code 38,384NAICS Code 33,339Show moreJupiter Endovascular Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Jupiter Endovascular your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Jupiter Endovascular, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Jupiter Endovascular
Funding: Get notified immidiatlly once Jupiter Endovascular has new funding data
Check if Jupiter Endovascular has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Jupiter Endovascular recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Jupiter Endovascular launches new products
Check out if Jupiter Endovascular is spiking on competitors!
Click to see if Jupiter Endovascular had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Jupiter Endovascular is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Jupiter Endovascular is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Jupiter Endovascular.
Jupiter Endovascular financials insights
Gather financial insights about Jupiter Endovascular, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$21M
2025
Series B
$40M
Jupiter Endovascular Tech Stack
A closer look at the technologies used by Jupiter Endovascular
Most Recent Scoops
Hiring Plans
Jupiter Endovascular has more open roles in Marketing than it has had at any time in the past 12 months.
Hiring Plans
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Open Position
Jupiter Endovascular News & Media
Jupiter Endovascular Completes Series B Round
MENLO PARK, CA, Jupiter Endovascular today announced it has closed an oversubscribed Series B financing round.Jupiter Endovascular Appoints Fred Ong as Chief Financial Officer - Business Wire
Jupiter Endovascular appoints Fred Ong as Chief Financial OfficerJupiter Endovascular Announces First U.S. Patient Treated With Vertex Pulmonary Embolectomy System Using Endoportal Control
MENLO PARK, Calif.--(BUSINESS WIRE)-- #FDA--Jupiter Endovascular announced the first U.S. patient treated with its novel Vertex Pulmonary Embolectomy System with Endoportal Control.Japan sees boost in corporate investment in Q3, while Israel experiences slump -
Japan saw an 80% rise in corporate backed funding rounds while India saw a 45% increase and Israel saw a 38% drop.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Jupiter Endovascular
Sign Up For FreeTo access detailed company insights
Jupiter Endovascular is a U.S.-based medical technology startup focused on advancing minimally invasive cardiovascular treatments through innovative catheter-based systems. Headquartered in Menlo Park, California, the company develops next-generation endovascular devices designed to improve the precision, stability, and effectiveness of interventio... Read More
